CD8A and neoplasm: Intravenous delivery of the probiotic Bifidobacterium bifidum to tumor-bearing mice activates tumor-specific IL-12 and IFN-γ, lymphocyte proliferation, and CD8+ cytolytic responses that suppress and eliminate tumor development, in contrast to oral administration alone.